Introduction {#sec1}
============

Visual fields (VFs) are critical for glaucoma diagnosis, gauging disease severity and monitoring for progression.[@bib1]^--^[@bib3] The utility of VFs in clinical decision making is dependent on test reliability. This is particularly crucial when deciding whether to make treatment decisions (i.e., advancement of therapy) based on VF data.

Previous studies have aimed to identify criteria for assessing whether a VF is reliable. Early researchers took a qualitative approach to VF reliability, classifying VFs as either reliable or unreliable.[@bib1]^,^[@bib4] This binary assessment was based on cutoffs for the percent abnormal catch trials of false positives (FPs), false negatives (FNs), or fixation losses (FLs) for a particular VF. However, these binary classifications preclude a more nuanced assessment of whether a VF should be trusted. We recently developed a quantitative model for the degree to which a VF was likely to deviate from its true value using a large dataset of VFs from glaucoma patients and suspects.[@bib5] In that study, FPs, FNs, and test duration (TD) all significantly affected reliability; FLs, on the other hand, had little effect on reliability.[@bib5] Based on those data, disease severity-specific standards for quantifying VF reliability were proposed.

Although our previous work helps the clinician understand the degree to which a VF deviates from its true value, in day-to-day clinical practice it is often more important to know how likely a VF is to deviate significantly from its true value. In other words, with what degree of FPs, FNs, FLs, or TD is a VF mean deviation (MD) likely to be 1 dB or more away from its expected value? In addition, it is important to know in which direction a VF deviates from expected (i.e., better than expected or worse than expected). A VF that is worse than expected has overly poor sensitivity that could falsely suggest disease progression; this is important to identify because acting on these results could subject a patient to unnecessary risks of treatment. Conversely, a better-than-expected VF has overly good sensitivity that can mask true disease progression.

In this study, we build on our prior work and create a predictive model that provides information on the likelihood of lower- or higher-than-expected sensitivity.

Methods {#sec2}
=======

The study protocol was approved prospectively by the Johns Hopkins institutional review board and adhered to the tenets of the Declaration of Helsinki. A waiver of consent was obtained to review VF data and obtain patient information via chart review. The study was Health Insurance Portability and Accountability Act compliant.

Study Participants {#sec2-1}
------------------

Patients included in this study were 18 years of age or older and were evaluated at the Wilmer Eye Institute Glaucoma Center of Excellence between 2002 and 2012, as previously described.[@bib5] All study participants had a glaucoma-related diagnosis (glaucoma suspect or any other form of glaucoma). All eyes that were analyzed had five or more VFs that were obtained with the Humphrey Field Analyzer (HFA II, Carl Zeiss Medical Technologies Inc., Dublin, CA) using the Swedish Interactive Threshold Algorithm (SITA) standard test protocol and the 24-2 pattern. Patients could have either one or both eyes included in the analyses. Only VFs with a MD greater (better) than -20 dB were included in the analyses.

VF and Clinical Data Collection {#sec2-2}
-------------------------------

VF data were retrieved for eyes meeting the inclusion criteria listed previously. MD was used as the measure of disease severity: MD \>−6 was defined as mild disease, −12 \< MD ≤−6 as moderate disease, and −20 \< MD ≤−12 as severe disease. VF metrics potentially affecting the reliability of measured MD were examined, including the TD and the percentage of FL, FP, and FN. The time and date of each VF test was obtained and categorized as early morning (7-10 AM), late morning (10 AM to noon), early afternoon (noon to 2 PM), or late afternoon (2-5 PM). The quarter of the year was also recorded (1 = winter, 2 = spring, 3 = summer, 4 = fall). A chart review was performed to determine patient age, sex, race, and clinical characteristics for all study subjects ([Table 1](#tbl1){ref-type="table"} and Supplementary Table S1).

###### 

Demographic and Visual Field Characteristics of Study Patients

  Total No. of Subjects                           909
  ----------------------------------------- ---------------
  Total no. eyes                                 1,538
  Mean no. of fields per eye (SD)              6.7 (1.8)
  Total no. of fields                           10,262
  Age at first VF, mean (SD)                  64.9 (11.8)
  Gender                                    
   Male (%)                                   497 (54.7%)
   Female (%)                                 412 (45.3%)
  Race                                      
   White (%)                                  594 (65.3%)
   Black (%)                                  232 (25.5%)
   Asian (%)                                   83 (9.1%)
  Baseline disease severity (no. of eyes)   
   Mild (MD \>−6 dB) (%)                     1,110 (72.2%)
   Moderate (−12 \<MD ≤−6) (%)                262 (17.0%)
   Severe (−20 \< MD ≤−12) (%)                166 (10.8%)

SD, standard deviation.

Modeling of VF Reliability {#sec2-3}
--------------------------

VF reliability was computed as the difference between observed and predicted MD (MD~observed~ − MD~predicted~) and referred to as ΔMD. The process for deriving ΔMD is shown in [Figure 1](#fig1){ref-type="fig"}. First, the predicted MDs were calculated for eligible VF tests using a linear mixed-effects regression model. The dependent variable in this model was the MD for each eligible VF test in the database; the independent variables are summarized in Supplementary Table S1. Because the baseline disease condition categories generated from the first VF MD and the eye-specific average VF MD were used as covariates, first VF MDs were not included in the sample used in the regression model. A linear mixed-effects regression model approach was used to account for clustering of different VF tests within the same eye within the same patient. The model used random intercepts, random slopes, and an unstructured variance-covariance matrix. Next, ΔMD was calculated as a continuous, directional measure of reliability for each VF test included in the study by subtracting the predicted MD obtained from the linear mixed effects model from the actual observed MD for that VF test (ΔMD = MD~observed ~− MD~predicted~). VFs with an observed MD value within 1 dB of the predicted MD (\|ΔMD\| ≤1 dB) were defined as having an "expected" sensitivity. VFs with an observed MD at least 1 dB worse than predicted (ΔMD \<−1 dB) had lower than expected sensitivity (worse-than-expected VF). VFs with an observed MD at least 1 dB greater than predicted (ΔMD \>1 dB) had higher than expected sensitivity (better-than-expected VF).

![Depiction of the difference in measured versus predicted MD and identification of visual fields with higher than expected and lower than expected sensitivity. (A) Schematic shows how ΔMD was calculated. The predicted MD at each time point was calculated using a mixed-effects linear regression model using the set of input variables listed in Supplementary Table S1. The ΔMD was obtained by subtracting the predicted MD from the observed MD at that point (ΔMD = MD~observed~ -- MD~predicted~). (B) Visual fields with lower than expected sensitivity were those in which the observed MD was worse than predicted (ΔMD \<−1), whereas VFs with higher than expected sensitivity were those in which the observed MD was better than predicted (ΔMD \>1). (Figure adapted from Yohannan et al.[@bib5])](tvst-9-1-4-f001){#fig1}

Modeling Higher or Lower Than Expected Sensitivity {#sec2-4}
--------------------------------------------------

Predictors of lower (ΔMD \<−1 dB) and higher (ΔMD \>1 dB) than expected sensitivity were identified with multinomial logistic mixed-effects regression models with a random intercept for patients and a random intercept for eyes to account for the correlations at the patient and eye level. In these models, the dependent variable was the category of ΔMD (−1 dB ≤ ΔMD ≤1 dB, ΔMD \<−1 dB, or ΔMD \>1 dB); the reference group for the dependent variable was the \|**Δ**MD\| ≤1 group (i.e., the group with observed MD close to that predicted). The independent variables included age, day of the week, quarter of the year, time of day, and the interaction terms between the baseline severity of VF loss and FLs, FPs, FNs, and TD to account for the fact that the effects of FL, FP, FN, and TD on ΔMD vary by the severity of VF loss. Relative risk (RR) was calculated for the effect of each factor on ΔMD reliability assuming all other factors are held constant. For FP, FN, and FL, the RRs were calculated per 10% increase in abnormal catch trials. For TD, the RRs were calculated per 1-minute increase in TD. All statistical analyses were performed in STATA statistical software: release 14 (StataCorp LP, College Station, TX).

Results {#sec3}
=======

A total of 10,262 VFs from 1538 eyes of 909 subjects with manifest or suspect glaucoma were examined. Subjects performed a mean of 6.7 (standard deviation, 1.8) VFs per eye. Demographic data are presented in [Table 1](#tbl1){ref-type="table"}. There were 6842 VFs with an expected sensitivity (\|ΔMD\| ≤1 dB), 1775 VFs with lower than expected sensitivity, and 1645 VFs with higher than expected sensitivity ([Table 2](#tbl2){ref-type="table"}).

###### 

Characteristics of Visual Fields Grouped by Normal, Lower than Expected, or Higher than Expected Sensitivity

                                   \|ΔMD\| ≤1      ΔMD \<−1       ΔMD \>1     
  ------------------------------ -------------- -------------- -------------- ---------
  Baseline disease severity                                                   \<0.001
  Mild (MD \>−6 dB) (%)           5409 (79.1%)   1051 (59.2%)   1002 (60.9%)  
  Moderate (−12 \< MD ≤−6) (%)    905 (13.2%)    431 (24.3%)    418 (25.4%)   
  Severe (−20 \<MD ≤−12) (%)       528 (7.7%)    293 (16.5%)    225 (13.7%)   
  Fixation losses                                                             \<0.001
   0∓10%                          3643 (53.3%)   914 (51.6%)    687 (41.9%)   
   10∓20%                         1318 (19.3%)   379 (21.4%)    330 (20.1%)   
   \>20%                          1872 (27.4%)   479 (27.0%)    624 (38.0%)   
  False positives                                                             \<0.001
   0∓10%                          6311 (92.2%)   1638 (92.3%)   1355 (82.4%)  
   10∓20%                          434 (6.3%)     111 (6.3%)     151 (9.2%)   
   \>20%                           97 (1.4%)      26 (1.5%)      139 (8.4%)   
  False negatives                                                             \<0.001
   0∓10%                          6201 (90.6%)   1347 (75.9%)   1279 (77.8%)  
   10-20%                          564 (8.2%)    326 (18.4%)    284 (17.3%)   
   \>20%                           77 (1.1%)      102 (5.7%)     82 (5.0%)    
  Test duration, min                                                          \<0.001
   \<6                            4325 (63.2%)   510 (28.7%)    707 (43.0%)   
   6-8                            2216 (32.4%)   979 (55.2%)    719 (43.7%)   
   \>8                             301 (4.4%)    286 (16.1%)    219 (13.3%)   
  Time of day of VF                                                           0.001
   7∓10 AM                        1861 (27.2%)   409 (23.0%)    438 (26.6%)   
   10 AM∓12 PM                    1802 (26.3%)   463 (26.1%)    439 (26.7%)   
   12∓2 PM                        1549 (22.6%)   407 (22.9%)    371 (22.6%)   
   2∓5 PM                         1630 (23.8%)   496 (27.9%)    397 (24.1%)   
  Quarter of the year                                                         0.032
   First (winter)                 1520 (22.2%)    381 (21.5)     409 (24.9)   
   Second (spring)                1800 (26.3)     460 (25.9)     449 (27.3)   
   Third (summer)                 1647 (24.1)     464 (26.1)     409 (24.9)   
   Fourth (fall)                  1875 (27.4)     470 (26.5)     378 (23.0)   

Note: The *P* values are derived from mixed effects models for the VF reliability measures.

Factors predicting lower or higher than expected VF sensitivity {#sec3-1}
---------------------------------------------------------------

There were significant differences among the three groups across all measured VF metrics in a bivariate analysis ([Table 2](#tbl2){ref-type="table"}). In the multivariate analysis, compared with VFs with mild damage (MD \>−6), those with severe (−20 \< MD ≤−12) damage were more likely to have lower than expected sensitivity (RR = 1.33, *P* \< 0.05) ([Table 3](#tbl3){ref-type="table"}). Moderate (−12 \< MD ≤−6) and severe disease also increased the likelihood of a higher than expected sensitivity (RR = 2.57 and 2.44, respectively; *P* \< 0.001).

###### 

Patient and Test Factors Influencing the Likelihood of Lower Than Expected and Higher Than Expected Visual Field Sensitivity

  --------------------------------------------------------------------------------------------------------------------------------------------
                                                            ΔMD \<−1       ΔMD \>1                                     
  --------------------------------- ------------------ ------------------- ----------------------- ------------------- -----------------------
                                                                                                                       

  Disease severity                  Mild (MD \>−6)             Ref         \-                              Ref         \-

                                    Moderate                  1.01         0.910                          2.57         **\<** **0** **.001**

                                    (−12 \< MD ≤−6)       (0.83--1.23)                                (2.07--3.20)     

                                    Severe                    1.33         **0.036**                      2.44         **\<** **0** **.001**

                                    (−20 \< MD ≤−12)      (1.02--1.73)                                (1.77--3.38)     

                                                                                                                       

  False positives (10% increase)    None/mild           0.47 (0.40--0.56)  **\<** **0** **.001**    2.14 (1.85--2.48)  **\<** **0** **.001**

                                    Moderate            0.52 (0.41--0.66)  **\<** **0** **.001**    2.93 (2.28--3.77)  **\<** **0** **.001**

                                    Severe              0.49 (0.34--0.70)  **\<** **0** **.001**    2.99 (2.06--4.36)  **\<** **0** **.001**

                                                                                                                       

  False negatives (10% increase)    None/mild           1.50 (1.28--1.75)  **\<** **0** **.001**    0.98 (0.82--1.18)  0.841

                                    Moderate            1.19 (1.02--1.38)  **0.023**                1.02 (0.86--1.22)  0.802

                                    Severe              1.10 (0.95--1.27)  0.222                    1.18 (0.98--1.42)  0.074

                                                                                                                       

  Fixation losses (10% increase)    None/mild           0.91 (0.88--0.95)  **\<** **0** **.001**    1.01 (0.97--1.05)  0.622

                                    Moderate            0.96 (0.90--1.02)  0.213                    1.11 (1.03--1.19)  **0.005**

                                    Severe              0.96 (0.88--1.04)  0.287                    1.15 (1.05--1.26)  **0.003**

                                                                                                                       

  Test duration (1-min. increase)   None/mild           2.12 (1.95--2.30)  **\<** **0** **.001**    0.90 (0.81--1.00)  **0.048**

                                    Moderate            1.58 (1.41--1.78)  **\<** **0** **.001**    0.72 (0.62--0.82)  **\<** **0** **.001**

                                    Severe              1.36 (1.18--1.56)  **\<** **0** **.001**    0.76 (0.63--0.91)  **0.003**

                                                                                                                       

  Time of day of VF                 7am-10am                   Ref         \-                              Ref         \-

                                    10am-12pm           1.09 (0.93--1.27)  0.275                    0.97 (0.82--1.15)  0.758

                                    12pm-2pm            1.07 (0.91--1.62)  0.399                    0.92 (0.77--1.10)  0.371

                                    2pm-5pm             1.27 (1.09--1.74)  **0.003**                0.94 (0.79--1.13)  0.513

                                                                                                                       

  Quarter of the year               First (winter)             Ref         \-                              Ref         \-

                                    Second (spring)     1.08 (0.92--1.26)  0.362                    0.95 (0.81--1.13)  0.583

                                    Third (summer)      1.19 (1.01--1.39)  **0.033**                0.89 (0.75--1.06)  0.186

                                    Fourth\             1.08 (0.92--1.26)  0.352                    0.74 (0.62--0.88)  **0.001**
                                    (fall)                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------

Bold face type in table indicates statistically significant results (p \< 0.05).

FPs decreased the likelihood of a lower than expected sensitivity at all stages of disease severity (RR = 0.47, 0.52, and 0.49 per 10% FPs for mild, moderate, and severe disease; *P* \< 0.001) ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}A). On the other hand, FPs increased the likelihood of a higher than expected sensitivity at all disease severities (RR = 2.14, 2.93, and 2.99 per 10% FPs for mild, moderate, and severe disease; *P* \< 0.001) ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}B).

![Influence of false positives, false negatives, fixation losses, and test duration on the likelihood of lower or higher than expected visual field sensitivity across the range of observed values. (A) False positives decrease the likelihood of a lower-than-expected sensitivity at all stages of disease severity. (B) False positives also increase the likelihood of a higher-than-expected sensitivity at all stages of disease severity. (C) False negatives increase the likelihood of a lower-than-expected sensitivity in mild and moderate disease. There was no significant effect in severe disease (*P* \> 0.05). (D) False negatives have no significant effect on the likelihood of higher-than-expected sensitivity (*P* \> 0.05). (E) Fixation losses slightly decrease the likelihood of lower-than-expected sensitivity in early disease. There was no significant effect in moderate and severe disease. (F) Fixation losses have a mild effect on the likelihood of higher-than-expected sensitivity in moderate and severe disease. (G) Longer test duration increases the likelihood of a lower-than-expected sensitivity at all disease stages. (H) Longer test duration decreases the likelihood of a higher-than-expected sensitivity at all stages of disease severity.](tvst-9-1-4-f002){#fig2}

FNs increased the likelihood of a lower than expected sensitivity in mild (RR = 1.5 per 10% FN, *P* \< 0.001) and moderate (RR = 1.19 per 10% FN, *P* = 0.02) disease, but not in severe disease (RR = 1.10, *P* = 0.2) ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}C). FNs did not significantly affect the likelihood of a higher than expected sensitivity (*P* \> 0.05 for all stages of disease) ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}D).

FLs decreased the likelihood of lower than expected sensitivity in mild disease (RR = 0.91 per 10% FL, *P* \< 0.001), and increased the likelihood of higher than expected sensitivity in moderate (RR = 1.11 per 10% FL, *P* \< 0.01) and severe (RR = 1.15 per 10% FL, *P* \< 0.01) disease, though the effect sizes were small ([Table 3](#tbl3){ref-type="table"} and [Figs. 2](#fig2){ref-type="fig"}E, [2](#fig2){ref-type="fig"}F). Of note, 687 (6.7%) of all VFs had zero FPs, FNs, or FLs; among these VFs, 193 (26.6%) had either lower or higher than expected sensitivity (data not shown in tables).

Longer TD increased the likelihood of a lower than expected sensitivity at all stages of disease severity (RR = 2.12, 1.58, and 1.36 per 1-minute increase in TD for mild, moderate, and severe disease; *P* \< 0.001) ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}G). Also, VFs with short TD almost never had lower than expected sensitivity ([Fig. 2](#fig2){ref-type="fig"}G). Increased TD also decreased the likelihood of higher than expected sensitivity at all disease severities (RR = 0.9, 0.72, and 0.76 per 1-minute increase in TD for mild, moderate, and severe disease; *P* \< 0.05) ([Table 3](#tbl3){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}H). The trend for an association between increased TD and lower than expected sensitivity was also confirmed within each of the disease severity bins. A 1-minute increase in TD results in a 1-dB decrease in ΔMD in the mild glaucoma group (95% confidence interval \[CI\], −1.06, −0.93), a 0.76-dB decrease in ΔMD in the moderate glaucoma group (95% CI, −0.87, −0.65), and a 0.33-dB decrease in ΔMD in the severe glaucoma group (95% CI, −0.47, −0.19).

VF tests taken in the late afternoon (2-5 PM) were more likely to have a lower than expected sensitivity compared with early morning tests (7-10 AM) (RR = 1.27, *P* \< 0.01) ([Table 3](#tbl3){ref-type="table"}). Tests taken in late morning (10 AM-12 PM) or early afternoon (12-2 PM) did not differ significantly from early morning tests (7-10 AM) (*P* \> 0.05). No time of day was associated with a higher likelihood of a higher than expected sensitivity (*P* \> 0.05). VFs taken in the summer tended to have a higher likelihood of lower than expected sensitivity compared with VFs taken in the winter (RR: 1.19, *P* = 0.03), and VFs taken in the fall had a lower likelihood of higher than expected sensitivity compared with those taken in the winter (RR: 0.74, *P* = 0.01) ([Table 3](#tbl3){ref-type="table"}).

Discussion {#sec4}
==========

In our models designed to gauge the likelihood of VF reliability, FNs and longer TD increased the likelihood of a worse-than-expected MD, whereas FPs increased the likelihood of a better-than-expected MD. Late afternoon tests also increased the likelihood of a worse-than-expected MD compared with early morning tests. Finally, severe VF damage increased variability of MD in both directions, and thus were noted to have a greater likelihood of both a worse-than-expected and better-than-expected MD. Even in VFs without any FPs, FNs, and FLs, 26.6% were either better or worse than expected. Our findings are important to bear in mind when interpreting VFs because acting on a series of worse-than-expected VFs can lead to unnecessary treatment, whereas better-than-expected VFs could mask true progression.

The reliability measures identified in this study hold important practical implications for day-to-day clinical practice. First, they highlight the importance of taking into consideration FPs, TD, FNs, and FLs when interpreting VFs. In our previous work, we showed that FPs have the strongest impact on the ΔMD for a given VF, with greater effects noted in more severe disease.[@bib5] The results of this study show that FPs have the greatest effect on the likelihood of poor VF reliability, with a particularly pronounced effect in more severe disease. Similar to this study, TD had the second largest effect on the ΔMD in our prior study,[@bib5] followed by FNs and FLs, as judged by the magnitude of RR. The direction of effect of each of these variables on the ΔMD in our prior study (i.e., increase or decrease in ΔMD) also correlates with the direction of effect on the likelihood of VF reliability (i.e., better than expected or worse than expected). FLs, while demonstrating a statistically significant effect on reliability in some models, do not appear to have a clinically meaningful effect in this population of experienced VF takers given the small odds ratios, consistent with our prior work.[@bib5] The relative unimportance of FLs may be due to the fact that FLs can occur frequently when the blind spot is mismapped, with small head tilts and other changes in patient positioning during VF testing, each of which would not be expected to also produce significant errors in overall sensitivity.[@bib5]^--^[@bib7] Of note, although mismapping of the blind spot would not be expected to significantly affect the MD of the entire VF, it may cause local impacts in the area of mismapping (affecting the reliability of sensitivities of specific points, which might be important in pointwise analyses).

We decided to consider poor reliability from a better-than-expected and worse-than-expected MD as separate outcomes because the clinical implications of these two outcomes are distinct. Specifically, VFs with a better-than-expected sensitivity (i.e., from FPs or, to a much lesser extent, FLs) could mask true disease progression. These tests may therefore need to be repeated, particularly if there is a concern for progression based on other clinical parameters (i.e., intraocular pressure, visual symptoms, Optical Coherence Tomography findings, trajectory of the other eye). On the other hand, VFs likely to have a lower than expected sensitivity (i.e., from a long TD or a high number of FNs), particularly in the context of mild or moderate disease, may be repeated if it suggests actionable progression, but would not need to be repeated were it to indicate stable VF damage. Of note, FNs do not affect the likelihood of a worse-than-expected VF in severe disease, likely because of the variable response of diseased locations in advanced disease[@bib8] and that VF MD likely reaches a floor in advanced disease and therefore reduces the marginal impact of FNs in such cases. Therefore, high FNs in severe disease should not generally serve as grounds for discounting a VF suggestive of progression.

Interestingly, our results also demonstrate that 26.6% of VFs that have no FPs, FNs, or FLs still demonstrate a better or worse than expected MD. Thus, it is important to not consider changes in the VF MD in isolation. Rather, these changes should be considered in the context of other findings, including where the worse points in the VF are located, intraocular pressure, patient symptoms, and optic nerve structure.[@bib9]^,^[@bib10]

Another notable finding in our study was the effect of time of day on the likelihood of VF reliability because tests taken in late afternoon were 30% more likely to be worse than expected compared with early morning VF tests. These results corroborate the findings of a prior study that demonstrated that post-lunchtime VFs were 0.2 dB worse on average compared with early morning tests.[@bib7] Given these findings, it may be worthwhile to consider performing a morning VF test before making treatment decisions in a patient who shows worsening on an afternoon VF compared with a previously obtained morning VF. Additionally, scheduling a given patient to take VFs at one consistent time of day may reduce variability in testing results.

Our results also demonstrate a mild seasonal variation in the likelihood of a better- or worse-than-expected VF outcome. VFs done in the winter tend to have a higher likelihood of higher-than-expected sensitivity than VFs taken in the fall. Additionally, they have a lower likelihood of lower-than-expected sensitivity than VFs taken in the summer. Our prior work[@bib5] and the work of other authors[@bib7] support this idea of mild seasonal variance in VF performance, with VF performance being highest in the winter months. Prior experimental work has revealed that visual sensitivity tends to be higher in the winter in healthy subjects, which may help explain this mild association.[@bib11]^,^[@bib12]

One limitation of this work is that the predicted MD that was used to calculate ΔMD was based on modeling and there is no way to know the "true" level of expected VF loss at any point in time. The generalizability of our study to different perimeters and testing algorithms other than the SITA standard strategy and 24-2 pattern may also be limited; prior studies have shown, for instance, that there are overall significantly fewer FNs and FPs in tests incorporating SITA compared with a full threshold algorithm.[@bib13]^,^[@bib14] Our analyses also did not include some factors that have been shown to predict the reliability of VFs, including technician comments, patient experience with VF testing, or gaze tracking.[@bib15]^,^[@bib16] Last, our study did not use serial repeated measures of VFs to assess reliability; Bengtsson\'s approach of repeated measures (having patients repeat VF within 1 week) to measure reliability is certainly a viable alternative methodology, although it is impractical to apply to this methodology to a large sample of clinical patients.[@bib17]

In summary, we have created a predictive model for the likelihood of poor VF reliability using a large database of VFs from glaucoma patients and suspects. Utilization of these results in day-to-day practice will allow a clinician to best use VF results for glaucoma management.
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